Related Experiment Video

Updated: Apr 6, 2026

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

3.5K

Survival After Solid Cancers in Antithrombotic Trials

Victor L Serebruany1, Ales Tomek2, Moo Hyun Kim3

  • 1HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, MD.

The American Journal of Cardiology
|July 20, 2015
PubMed

Insights

Patient survival after solid cancer (SASC) in antithrombotic trials mirrors general population rates. This study found no significant difference in SASC when comparing trial data to SEER and WHO averages, reassuring for cancer patients on antithrombotics.

Area of Science:

  • Cardiology
  • Oncology
  • Clinical Trials

Background:

  • Antithrombotic medications are under scrutiny for potential impacts on cancer incidence.
  • Limited data exists on patient survival after solid cancer (SASC) within antithrombotic clinical trials.

Purpose of the Study:

  • To investigate and compare 1-year SASC rates in patients from antithrombotic trials against general population cancer survival data.
  • To determine if antithrombotic drug use affects outcomes for patients who develop cancer during trials.

Main Methods:

  • Utilized Food and Drug Administration (FDA) data on SASC from three major antithrombotic trials (TRITON, APPRAISE-2, ARISTOTEL).
  • Matched trial SASC data with cancer survival averages from the Surveillance, Epidemiology, and End Results (SEER) Program and World Health Organization (WHO) surveys.
  • Performed statistical analysis, including odds ratios and confidence intervals, to compare trial SASC rates with population averages.

Main Results:

  • SASC rates in the analyzed antithrombotic trials were approximately 70% for the first year of follow-up.
  • Statistical comparisons showed no significant difference between SASC rates in trials and SEER (OR 0.92, CI 0.53-1.59) or WHO (OR 0.99, CI 0.57-1.7) data.
  • The findings indicate that cancer survival in patients within these antithrombotic trials is consistent with general population estimates.

Conclusions:

  • Patient survival after solid cancer (SASC) in antithrombotic trials is comparable to that observed in the general population.
  • The use of antithrombotics in the context of these trials does not appear to negatively impact cancer survival rates.
  • These findings help address concerns regarding the interplay between antithrombotic therapy and cancer outcomes.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

6.4K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
838
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
489
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
672